#AACR26 spotlight: Carlota Pages-Geli, PhD, @KippWeiskopf lab, “Unbiased discovery of novel microphage-activating immunotherapies for ALK+ #NSCLC.”

💡Combining CD47 x TROP2 bispecific antibodies with lorlatinib produced synergistic anti-tumor effects.

#LungCancer https://t.co/Uqoiy10kH5